This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Raili Kauppinen, EAN 2020 – ENVISION Study in Patients With Acute Hepatic Porphyria

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 5th 2020

Raili Kauppinen (University Hospital of Helsinki, Finland) shares key findings and insights into the ENVISION study, which evaluated the efficacy and safety of givosiran, a subcutaneously administered RNA interference therapeutic targeting aminolevulinic acid synthase 1, in patients with acute hepatic porphyrias (ClinicalTrials.gov Identifier: NCT03338816).

Questions
1. Could you give us a brief overview of acute hepatic porphyria, its pathophysiology and manifestations? (
0:05)
2. What is givosiran and what is its mechanism of action? (
2:12)
3. What were the aims and design of the ENVISION study? (
2:50)
4. What have been the main efficacy and safety findings of this study? (
4:03)
5. What has been the impact of this on patients’ lives and on the current treatment paradigm? (
5:01)

Speaker disclosure: Raili Kauppinen reports receiving advisory board fees from Alnylam Pharmaceuticals, advisory fees from Recordati Rare Diseases, travel fees from Sanofi, and ownership of stock in the Orion Corporation.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup